File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors

TitleModulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors
Authors
Issue Date2012
PublisherLippincott Williams & Wilkins.
Citation
The 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO 2012), Chicago, IL., 1-5 June 2012. In Journal of Clinical Oncology, 2012, v. 30 n. 15 suppl., abstract no. e13589 How to Cite?
AbstractBACKGROUND: Tumor growth and angiogenesis are regulated by multiple cellular pathways, including the VEGF, mTOR, and EGFR pathways. We have previously reported our clinical experience combining Bev, Ev and Erl therapies. Taking advantage of the similarities between tumor growth and wound healing, we conducted a PD analysis of these agents using novel dermal wound angiogenesis assays. METHODS: Patients with advanced solid tumors received either 1) Bev-Ev doublet therapy; 2) Bev-Ev-Erl triplet therapy; 3) Ev monotherapy for 14 days followed by addition of Bev-Erl; 4) Erl monotherapy for 14 days followed by addition of Bev-Ev. Full-thickness dermal granulation biopsies were harvested; the phospho (p) and total (t) levels of VEGFR2, EGFR, and S6RP were measured at baseline, end of the monotherapy lead-in period (day 14), and 35 days post doublet or triplet therapy. A dermal wound angiogenesis assay, which quantifies peripheral wound vascularization was also incorporated in the study. RESULTS: 38 pts were evaluable for biomarker analysis. Wilcoxon signed rank tests indicated that both VEGFR2 and S6RP were significantly down-regulated after Bev-Ev-Erl triplet therapy: tVEGFR2 (q=5.1E-05), pVEGFR2 (q=0.01), tS6RP (q=0.007), pS6RP (q=9.7E-04). Levels of tVEGFR2 (q=5.5E-04) and pS6RP (q=6.9E-04) were also found to be significantly down-regulated after Bev-Ev doublet therapy. Ev monotherapy for 14 days led to significant tVEGFR2 down-regulation (q=0.035). No significant changes in EGFR levels were observed in any cohort. Additionally, Bev-Ev-Erl triplet therapy led to a slight decrease in dermal wound vascularization (p=0.098), which positively correlated with changes in tVEGFR2 levels (q=0.008). CONCLUSIONS: This is the first investigation evaluating the PD effects of VEGF, mTOR, and EGFR inhibition in a clinical wound-healing model. Our results indicate that targeting of all three pathways is associated with overall down-regulation of both VEGF and mTOR pathways. These data suggest that this dermal wound model can be used to quantify PD markers in evaluating multiple classes of targeted therapies.
DescriptionThis journal suppl. entitled: 2012 ASCO Annual Meeting Abstracts
Persistent Identifierhttp://hdl.handle.net/10722/195794
ISSN
2023 Impact Factor: 42.1
2023 SCImago Journal Rankings: 10.639

 

DC FieldValueLanguage
dc.contributor.authorJia, Jen_US
dc.contributor.authorLi, Hen_US
dc.contributor.authorDellinger, Aen_US
dc.contributor.authorPang, HMHen_US
dc.contributor.authorRussell, KBen_US
dc.contributor.authorHurwitz, Hen_US
dc.contributor.authorNixon, ABen_US
dc.date.accessioned2014-03-10T04:53:31Z-
dc.date.available2014-03-10T04:53:31Z-
dc.date.issued2012en_US
dc.identifier.citationThe 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO 2012), Chicago, IL., 1-5 June 2012. In Journal of Clinical Oncology, 2012, v. 30 n. 15 suppl., abstract no. e13589en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/195794-
dc.descriptionThis journal suppl. entitled: 2012 ASCO Annual Meeting Abstracts-
dc.description.abstractBACKGROUND: Tumor growth and angiogenesis are regulated by multiple cellular pathways, including the VEGF, mTOR, and EGFR pathways. We have previously reported our clinical experience combining Bev, Ev and Erl therapies. Taking advantage of the similarities between tumor growth and wound healing, we conducted a PD analysis of these agents using novel dermal wound angiogenesis assays. METHODS: Patients with advanced solid tumors received either 1) Bev-Ev doublet therapy; 2) Bev-Ev-Erl triplet therapy; 3) Ev monotherapy for 14 days followed by addition of Bev-Erl; 4) Erl monotherapy for 14 days followed by addition of Bev-Ev. Full-thickness dermal granulation biopsies were harvested; the phospho (p) and total (t) levels of VEGFR2, EGFR, and S6RP were measured at baseline, end of the monotherapy lead-in period (day 14), and 35 days post doublet or triplet therapy. A dermal wound angiogenesis assay, which quantifies peripheral wound vascularization was also incorporated in the study. RESULTS: 38 pts were evaluable for biomarker analysis. Wilcoxon signed rank tests indicated that both VEGFR2 and S6RP were significantly down-regulated after Bev-Ev-Erl triplet therapy: tVEGFR2 (q=5.1E-05), pVEGFR2 (q=0.01), tS6RP (q=0.007), pS6RP (q=9.7E-04). Levels of tVEGFR2 (q=5.5E-04) and pS6RP (q=6.9E-04) were also found to be significantly down-regulated after Bev-Ev doublet therapy. Ev monotherapy for 14 days led to significant tVEGFR2 down-regulation (q=0.035). No significant changes in EGFR levels were observed in any cohort. Additionally, Bev-Ev-Erl triplet therapy led to a slight decrease in dermal wound vascularization (p=0.098), which positively correlated with changes in tVEGFR2 levels (q=0.008). CONCLUSIONS: This is the first investigation evaluating the PD effects of VEGF, mTOR, and EGFR inhibition in a clinical wound-healing model. Our results indicate that targeting of all three pathways is associated with overall down-regulation of both VEGF and mTOR pathways. These data suggest that this dermal wound model can be used to quantify PD markers in evaluating multiple classes of targeted therapies.-
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins.en_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.titleModulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumorsen_US
dc.typeConference_Paperen_US
dc.identifier.emailPang, HMH: herbpang@hku.hken_US
dc.identifier.authorityPang, HMH=rp01857en_US
dc.identifier.volume30en_US
dc.identifier.issue15 suppl. (May 20 Supplement)-
dc.publisher.placeUnited Statesen_US
dc.identifier.issnl0732-183X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats